Therapeutic outcomes of older patients with acute myeloid leukemia
Pathology and Microbiology
To evaluate the therapeutic outcomes of acute myeloid leukemia (AML) in elderly Patients.
This study was conducted at the Aga Khan University Hospital, Karachi, Pakistan over 11 years from January 1997 to August 2008. This was a descriptive case series study. We investigated the impact of disease biology and various treatment protocols on the outcome in this population.
A total of 55 evaluable Patients (>60 years of age) were diagnosed with AML including 34 (61.8%) males and 21 (38.2%) females. The median age was 67 years (range 60-86 years) at the time of presentation. The AML was preceded by myelodysplastic syndrome in 15 (27.2%) Patients. High-risk cytogenetics were observed in 3 (5.4%) Patients. Forty Patients received palliative treatment while only 15 received chemotherapy. Of the last group with primary AML (n=10), there were 2 remitters, one showed resistant disease while 8 had induction death. The overall mean survival was 75.1 days (95% confidence interval: 46.7-103.5 days) in all Patients. There was no survival advantage in Patients treated with chemotherapy versus those conservatively treated.
We found high mortality among aged Patients with AML in our setting. Patients receiving chemotherapy were extremely intolerant to toxic drugs and succumbed earlier than Patients receiving palliative care only.
Saudi Medical Journal
(2010). Therapeutic outcomes of older patients with acute myeloid leukemia. Saudi Medical Journal, 31(5), 533-538.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/195